NEW YORK, May 10, 2022 /PRNewswire/ -- Weiss Law, a national shareholders' rights law firm, is investigating possible false claims, deceptive accounting and reporting practices, breaches of fiduciary duty, and violations of the federal securities laws by the Board of Directors and certain Company officers of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent" or the "Company"). According to a final report expected to be released today after a year-long investigation by the House of Representatives' Select Subcommittee on the Coronavirus Crisis, the Company, hired to produce hundreds of millions of coronavirus vaccine doses, hid from US Food and Drug Administration ("FDA") inspectors evidence of quality control problems in February 2021- six weeks before it alerted federal officials that 15 million doses were contaminated.
If you own Emergent shares and wish to discuss this investigation, or share information which you have, or if you have any questions concerning this notice or your rights or interests, visit our website at
https://www.weisslaw.co/news-and-cases/ebs
Or please contact:
Josh Rubin, Esq [email protected]
(212) 682-3025.
There is no cost or obligation to you.
A report released by the House and the Select Subcommittee on the Coronavirus Crisis found that nearly 400 million doses of coronavirus vaccine manufactured by Emergent were destroyed "due to poor quality control," including about 240 million doses in late 2020 and early 2021. The report, based on...
COLUMBUS, OH (WOWO) A legal dispute involving Columbus-based startup OH.io and three former executives has escalated with new court filings and a statement from their attorney disputing allegation...